Introduction {#s1}
============

Bioresorbable scaffolds (BRS) have been designed to overcome problems related to the long-term persistence of metallic stents implanted in coronary arteries.^[@ehw196C1],[@ehw196C2]^ Several randomized controlled trials (RCTs) comparing polymeric BRS with new-generation drug-eluting stents (DES) found similar clinical outcomes at 1 year. A recent meta-analysis, though, showed an increased risk of definite or probable scaffold thrombosis for BRS (1.3% compared with 0.5%).^[@ehw196C3]^ As the true benefit of BRS is expected to ensue later, long-term data of RCTs are awaited. So far, non-randomized studies up to 5 years showed promising outcomes.^[@ehw196C4],[@ehw196C5]^

Absorbable metal scaffolds constitute an attractive alternative to polymeric BRS, as they conform more to the technique of percutaneous coronary intervention with DES.^[@ehw196C6]^ We assessed a novel second-generation drug-eluting absorbable metal scaffold (DREAMS 2G), which has been redesigned iteratively by (i) improving the design of the magnesium backbone of its previous version^[@ehw196C7],[@ehw196C8]^ and (ii) using the same drug--polymer combination (sirolimus/poly-[l]{.smallcaps}-lactide) as the new-generation biodegradable polymer stent Orsiro (Biotronik AG, Buelach, Switzerland).^[@ehw196C9],[@ehw196C10]^ Six-month outcomes were recently published, showing favourable angiographic and clinical outcomes with a low rate of target lesion failure (TLF) and no definite or probable scaffold thrombosis.^[@ehw196C6]^ We aimed to evaluate if those results are sustained at 12 months, a time point when the magnesium scaffold is expected to be degraded.

Methods {#s2}
=======

Study design and population {#s2a}
---------------------------

A detailed description of the study has been recently published.^[@ehw196C6]^ In brief, BIOSOLVE-II is a prospective, multi-centre, first-in-man study to evaluate the safety and performance of DREAMS 2G (Biotronik AG, Buelach, Switzerland). The study is in compliance with the Declaration of Helsinki, Good Clinical Practice, ISO14155, and was approved by the institutional ethics committees at the participating 13 institutions in Europe, South America, and Asia. All patients provided written informed consent.

Eligible patients had stable or unstable angina or documented silent ischaemia, a maximum of two single *de novo* lesions in two separate coronary arteries, with a reference vessel diameter between 2.2 and 3.7 mm, a lesion length of ≤21 mm, and a diameter stenosis between 50 and 99%. Exclusion criteria included thrombus in the target vessel, severe calcification, three-vessel disease, ostial lesion, bifurcation lesion involving a side branch \>2.0 mm in diameter, target lesion located in or supplied by an arterial or venous bypass graft, and unsuccessful pre-dilatation. The full list of inclusion and exclusion criteria can be accessed at clinicaltrials.gov (NCT01960504).

Clinical follow-up was planned at 1, 6, 12, 24, and 36 months. Angiographic follow-up was scheduled at 6 months for all patients, an additional pre-specified imaging follow-up was scheduled at 12 months if subjects consented. A subgroup of 30 patients underwent intravascular ultrasound (IVUS), optical coherence tomography (OCT), and vasomotion testing at 6 months. At this time point, these patients were also asked to consent for voluntary IVUS, OCT, and vasomotion assessment at 12 months. Only patients without target lesion revascularization (TLR) were asked for additional 12-month imaging assessment.

Study device {#s2b}
------------

DREAMS 2G is a drug-eluting absorbable metal scaffold system comprising of an absorbable magnesium scaffold pre-mounted on a balloon-expandable delivery system. The scaffold is laser-polished and its surface is completely coated with bioresorbable poly-[l]{.smallcaps}-lactide, which incorporates sirolimus.^[@ehw196C6]^

Endpoints and definitions {#s2c}
-------------------------

The primary endpoint was in-segment late lumen loss (LLL) at 6-month follow-up. Secondary endpoints at 12 months were TLF, a composite of cardiac death,^[@ehw196C11]^ target-vessel myocardial infarction,^[@ehw196C12]^ and clinically TLR^[@ehw196C11]^; scaffold thrombosis^[@ehw196C11]^; in-scaffold and in-segment binary restenosis; diameter stenosis; and in-scaffold LLL.^[@ehw196C13]^

A clinical event committee adjudicated all adverse events, and an independent core laboratory (Cardialysis B.V., Rotterdam, The Netherlands) performed the quantitative coronary angiography (QCA), IVUS, and OCT analyses. Imaging analysis methods and definitions have been published previously.^[@ehw196C6]^

Procedure {#s2d}
---------

The device was available to operators in sizes 2.5 mm × 20 mm, 3.0 mm × 20 mm, or 3.5 mm × 25 mm. Pre-dilatation was mandatory; post-dilatation was left to the operator\'s discretion. Only one study device per lesion was allowed, although in bailout situations, a second DREAMS 2G could be used, and, in case of failure, an Orsiro DES. Dual antiplatelet therapy was recommended for a minimum of 6 months. The procedural details of vasomotion testing and imaging procedure are described elsewhere.^[@ehw196C6]^

Statistical analysis {#s2e}
--------------------

The sample size was calculated based on the primary endpoint in-segment LLL at 6 months and has been previously reported.^[@ehw196C6]^ The null hypothesis was a mean in-segment LLL at 6 months of ≥0.5 mm. An overall of 121 (101 + 20) subjects were scheduled to be enrolled, assuming an expected in-segment LLL mean of 0.45 mm, standard deviation of 0.2 mm, one-sided, significance level of 0.05, and 80% power.

The intention-to-treat analysis population was defined as patients for whom an investigational scaffold entered the guide catheter following the diagnostic angiogram. Patients not receiving a study device were included in the calculation of procedural success, but excluded from further analysis as defined in the study protocol. For serial imaging analysis, paired data were used.

Descriptive statistical methods were used. Means and standard deviations, medians and interquartile ranges (IQR), and 95% CIs were calculated as appropriate. For categorical data, absolute and relative frequencies were calculated and 95% CIs for proportions. *P*-values were calculated using paired *t*-test, Fisher\'s exact test, χ^2^ test, and Wilcoxon signed-rank test, where applicable. All statistical analyses were performed with SAS (version 9.3).

Role of the funding source {#s2f}
--------------------------

The study was sponsored by Biotronik AG, Buelach, Switzerland. The sponsor was involved in the design and conduction of the study, data collection, monitoring, and data analysis.

Results {#s3}
=======

Between October 2013 and May 2015, 123 subjects were enrolled. Clinical follow-up at 12 months was 98% (*Figure [1](#ehw196F1){ref-type="fig"}*). Baseline parameters are listed in *Table [1](#ehw196TB1){ref-type="table"}*. A comparison of baseline parameters of the angiographic and IVUS/OCT subgroups with serial 6- and 12-month evaluation compared with the overall population is provided in the [Supplementary material online, *Table S1*](#sup1){ref-type="supplementary-material"}. In two lesions, DREAMS 2G could not be implanted due to insufficient pre-dilatation; follow-up of these two subjects was consequently not included in this analysis.

###### 

Baseline clinical and lesion characteristics

                                                 *n* = 123
  ---------------------------------------------- --------------
  Mean age, years                                65.2 ± 10.3
  Male gender                                    78 (63.4)
  Hypertension                                   101 (82.1)
  Hyperlipidaemia                                74 (60.2)
  Diabetes                                       36 (29.3)
  History of smoking                             67 (54.5)
  Previous percutaneous coronary interventions   44 (35.8)
  CABG                                           8 (6.5)
  History of myocardial infarction               29 (23.6)
  Renal failure                                  4 (3.3)
  Congestive heart failure                       8 (6.5)
  History of stroke or TIA                       7 (5.7)
  Mean lesion length, mm^a^                      12.61 ± 4.53
  Mean reference vessel diameter, mm^2a^         2.68 ± 0.40
  AHA/ACC classification type B2/C^b^            53 (43.4)
  Moderate-to-severe calcification               13 (10.6)
  Thrombus                                       3 (2.4)

Data are shown as mean ± SD or *n* (%).

AHA/ACC, American Heart Association/American College of Cardiology; CABG, coronary artery bypass graft; TIA, transient ischaemic attack.

^a^ *n* = 120, in 3 subjects, images were not analysable.

^b^ *n* = 122, 1 subject not analysable.

![Patient flow chart. IVUS, intravascular ultrasound; OCT, optical coherence tomography. ^a^Two patients who did not receive an implant were used for calculation of device and procedural success only. ^b^Thirty-four visits were conducted by phone. ^c^Forty-five angiographic assessments of which two were excluded as they did not have matched projections recorded, one did not have a 6-month but only 12-month angiography.](ehw19601){#ehw196F1}

At baseline, 88 (71.5%) patients had stable angina, 17 (13.8%) unstable angina, and 18 (14.6%) silent ischaemia. At 12-month follow-up, 100 (86.2%) patients were symptom-free, 14 (12.1%) had stable angina (9 CCS class I and 5 CCS class II), 1 (0.9%) had silent ischaemia, and none had unstable angina. Fifty-seven patients (48.3%) were still on dual antiplatelet therapy at 12 months.

Paired QCA data could be obtained in 42 patients from seven centres at a mean follow-up time of 181 ± 17 days and 367 ± 17 days for 6- and 12-month assessments, respectively. Paired in-segment LLL at 6 and 12 months was 0.20 ± 0.21 mm (95% CI: 0.13;0.26) and 0.25 ± 0.22 mm (95% CI: 0.18;0.32), *P* = 0.117, Δ 0.05 ± 0.21 mm (95% CI: −0.01;0.12), and in-scaffold LLL 0.37 ± 0.25 mm (95% CI: 0.29;0.45) and 0.39 ± 0.27 mm (95% CI: 0.31;0.48), *P* = 0.446, Δ 0.03 ± 0.22 mm (95% CI: −0.04;0.10) (*Table [2](#ehw196TB2){ref-type="table"}*, *Figure [2](#ehw196F2){ref-type="fig"}*). The in-segment and in-scaffold LLL of the overall population at 6 months were 0.27 ± 0.37 and 0.44 ± 0.36 mm for the overall population (0.21 ± 0.28 and 0.37 ± 0.28 mm in patients without TLR). There was no statistically significant difference in baseline characteristics between this subgroup and the overall patient population.

###### 

Quantitative coronary angiographic analysis (paired data, *n* = 42)

                                          Pre-procedure   Post-procedure   6 months      12 months
  --------------------------------------- --------------- ---------------- ------------- -------------
  Reference vessel diameter in-segment    2.74 ± 0.35     2.75 ± 0.35      2.60 ± 0.38   2.60 ± 0.41
  Reference vessel diameter in-scaffold   NA              2.84 ± 0.37      2.66 ± 0.34   2.64 ± 0.44
  Minimum lumen diameter in-segment       1.22 ± 0.33     2.25 ± 0.41      2.01 ± 0.38   1.96 ± 0.41
  Minimum lumen diameter in-scaffold      NA              2.54 ± 0.33      2.14 ± 0.38   2.10 ± 0.41
  Acute gain in-segment                   NA              1.00 ± 0.38      NA            NA
  Acute gain in-scaffold                  NA              1.29 ± 0.34      NA            NA
  Diameter stenosis in-segment            55.2 ± 10.9     18.7 ± 6.8       22.6 ± 9.2    24.7 ± 10.6
  Diameter stenosis in-scaffold           NA              10.4 ± 6.0       19.6 ± 8.4    20.4 ± 8.6
  Binary restenosis in-segment, %         NA              NA               0 (0)         2 (4.8)
  Binary restenosis in-scaffold, %        NA              NA               0 (0)         0 (0)
  Late lumen loss in-segment              NA              NA               0.20 ± 0.21   0.25 ± 0.22
  Late lumen loss in-scaffold             NA              NA               0.37 ± 0.25   0.39 ± 0.27

Data are shown as mean ± SD or *n* (%). All measurements are in mm if not otherwise specified. There was no significant difference in outcomes between 6 and 12 months.

NA, not applicable.

![Cumulative frequency curves for in-segment (*A*) and in-scaffold (*B*) late lumen loss. Six- and twelve-month serial analysis of late lumen loss observed in BIOSOLVE-II compared with BIOSOLVE-I using the precursor device DREAMS first generation.](ehw19602){#ehw196F2}

Serial IVUS and OCT analyses at 6 and 12 months were performed in 11 patients (respective data listings are provided in the [Supplementary material online, *Tables S2 and S3*](#sup1){ref-type="supplementary-material"}). Paired IVUS parameters did not differ significantly between 6 and 12 months (median minimum lumen area of 4.80 vs. 4.69 mm^2^, *P* = 0.700), except for the number of patients with incomplete strut apposition, which was reduced to zero at 12 months ([Supplementary material online, *Table S4*](#sup1){ref-type="supplementary-material"}; *Figure [3](#ehw196F3){ref-type="fig"}*). By OCT, the median minimal lumen area decreased from 4.58 mm^2^ at 6 months to 4.19 mm^2^ at 12 months, *P* = 0.032. No intraluminal mass was observed at any time. *Figure [4](#ehw196F4){ref-type="fig"}* shows that at 6 and 12 months, strut-like remnants are only visible by IVUS but not by OCT.

![Serial changes of intravascular ultrasound parameters in 11 patients. Only a very small neo-intimal hyperplasia area is visible (7 o\'clock). Δ indicates the difference between follow-ups in mm^2^ \[95% CI\].](ehw19603){#ehw196F3}

![Serial angiographic, optical coherence tomography, intravascular ultrasound, and virtual histology of a patient implanted with DREAMS 2G. Matched images show that at 6 months, struts are hardly discernible by optical coherence tomography and the scaffold strut that had covered the side branch post-procedure (12 o\'clock) had disappeared. At 12 months, the vessel surface appears even smoother than at 6 months (2 o\'clock). On intravascular ultrasound, strut remnants are still discernible at follow-up. Assessed by virtual histology, the white colour coding of the scaffold struts disappears over time demonstrating the absorption process. A--A′, scaffolded segment; P, proximal reference; D, distal reference.](ehw19604){#ehw196F4}

Serial vasomotion at 6 and 12 months was tested in 14 patients; thereof 11 (79%) had a change of \>3% to the mean lumen diameter after infusion or injection of acetylcholine (*Figure [5](#ehw196F5){ref-type="fig"}*). The median percentage change in mean lumen diameter between pre-and post-acetylcholine was −2.6% (IQR: −6.4 to −0.6%, mean −5.1 ± 7.7%) at 6 months and −3.4% (IQR: −9.4 to 3.2%, mean −3.4 ± 11.0%) at 12 months; the percentage change in mean lumen diameter between post-acetylcholine and nitroglycerine was 3.4% (IQR: 1.1--9.2%, mean 5.8 ± 6.4%) and 6.7% (IQR: 0.0--17.4%, mean 8.2 ± 10.6%), respectively.

![Change in vasomotion between 6 and 12 months. Percentage change in mean lumen diameter after acetylcholine and after subsequent intracoronary injection of nitroglycerine at 6 and 12 months in 14 patients. Each line reflects one patient. The ends of the boxes represent the first and third quartiles, the band the median, and the crystal the mean. There was no statistical significant difference between 6 and 12 months (*P* = 0.808 for acetylcholine and *P* = 0.626 for nitroglycerine). ACH, acetylcholine; Nitro, nitroglycerine.](ehw19605){#ehw196F5}

Target lesion failure at 12 months was observed in 4/118 patients (3.4%, 95% CI: 0.9--8.4). No events beyond 6 months occurred. Specifically, one death (0.8%) of unknown cause on day 134 post-procedure was classified as cardiac death. One target-vessel myocardial infarction (0.8%) was due to temporary no-reflow after scaffold implantation. Clinically driven TLR was performed in two patients (1.7%). One patient died of cancer prior to 6-month follow-up. No definite or probable scaffold thrombosis was observed. Further details are provided in the [Supplementary material online, *Table S5*](#sup1){ref-type="supplementary-material"}.

Discussion {#s4}
==========

The main findings of our study are stability of the angiographic and clinical outcomes of the second-generation device DREAMS 2G between 6 and 12 months. There was no definite or probable scaffold thrombosis up to 12 months and no TLF beyond 6 months. These findings are relevant as ∼95% of the magnesium scaffold is expected to be absorbed within 12 months.^[@ehw196C6]^ The importance of this time point for DREAMS 2G is reflected in the recently published European Society of Cardiology--European Association of Percutaneous Cardiovascular Interventions report on the evaluation on coronary stents, which states that 'for bioresorbable stents, critical time points of follow-up will depend on the pace of biodegradation and should cover complete resorption'.^[@ehw196C13]^

Compared with the first generation, DREAMS 2G has markedly improved angiographic performance parameters also at 12 months (in-segment LLL of 0.25 ± 0.22 mm vs. 0.39 ± 0.33 mm and in-scaffold LLL of 0.39 ± 0.27 vs. 0.52 ± 0.39 mm).^[@ehw196C7]^ There are reports that found a significant relationship between LLL and TLR even in patients with a LLL of \<0.5mm, but to a lesser extent than above 0.5 mm.^[@ehw196C14]^ In other studies with permanent metallic stents, an in-segment LLL of ≤0.5 mm has been associated with a maximal TLR rate of 5%^[@ehw196C15]^ and a binary restenosis rate of 5%.^[@ehw196C16]^ Furthermore, in an evaluation from 11 RCTs, Pocock *et al*.^[@ehw196C17]^ pointed out that a 12-month in-segment LLL of \<0.3 mm and in-stent LLL of \<0.4 mm were associated with very low TLR rates and that further reductions in LLL are unlikely to reduce clinical restenosis. Correspondingly, a meta-analysis of RCTs showed that BRS had similar 12-month TLR rates as new-generation DES despite inferior LLL.^[@ehw196C3]^ This might also explain the good clinical outcomes in our series despite a higher LLL. Specifically, compared with recently established objective performance criteria for coronary stent trials at 9--12 months,^[@ehw196C13]^ our series had inferior LLL \[mean in-scaffold LLL of 0.39 ± 0.27 mm compared with a median of 0.18 mm (IQR: 0.13--0.25) for new-generation DES\], but comparable clinical outcomes \[TLR of 1.7% compared with 2.91% (IQR: 1.67--5.94) for new-generation DES, definitive stent thrombosis of 0.0% compared with 0.47% (IQR:0.28 to 0.72), respectively\].

One of the encouraging finding is the persisting absence of definite or probable scaffold thrombosis in this trial and any other trial with precursor devices of DREAMS 2G, tested in the PROGRESS or BIOSOLVE-I study.^[@ehw196C7],[@ehw196C8]^ However, this has to be interpreted with the caveat that (i) only 123 patients were enrolled, (ii) the results were not obtained in an all-comers patient population, (iii) randomized controlled data are missing yet, and (iv) dual antiplatelet therapy was recommended for at least 6 months, and nearly half of the patients were still on dual antiplatelet therapy at 12 months. Still, these results are promising in the context of a recent meta-analyses where higher scaffold thrombosis rates (mostly acute and subacute) were reported for patients treated with polymeric BRS compared with DES.^[@ehw196C3],[@ehw196C18]^ Notably, in ABSORB cohort A and B, there was also no scaffold thrombosis except one iatrogenic scaffold thrombosis with subsequent myocardial infarction.^[@ehw196C4],[@ehw196C5]^ Nevertheless, there are several factors indicating that DREAMS 2G might have a reduced risk for thrombosis: At 12 months, struts were not discernible by OCT, but IVUS showed strut-like remnants. In the case example of *Figure [4](#ehw196F4){ref-type="fig"}*, the white colour coding of the scaffold struts disappears over time demonstrating the absorption process. This is most likely explained by the biodegradation of magnesium. Approximately 95% of the magnesium is converted at 12 months.^[@ehw196C6]^ In brief, the biodegradation of magnesium occurs by means of anions and cations exchange, magnesium hydroxide is formed, and in a second step, magnesium hydroxide is converted to amorphous calcium phosphate.^[@ehw196C22],[@ehw196C23]^ Hence, at 12 months, elution of magnesium from the metallic backbone is usually completed, and the strut areas are mostly filled by amorphous calcium phosphate with high water content, which is not discernible by OCT but to some extent by IVUS. Amorphous calcium phosphate should not be misinterpreted as calcification that is associated with an echo shadowing that was not documented behind the scaffold remnants in IVUS.

a.  In 30 patients assessed up to 6 months^[@ehw196C6]^ and 11 up to 12 months, no intraluminal mass was detected by OCT. At 6 months, no mal-apposed struts were present, because the scaffold struts were already embedded into the vessel wall. Furthermore, in the presence of nearly full absorption of the magnesium scaffold at 12 months,^[@ehw196C6]^ late acquired mal-apposition appears to be impossible. This is important since recent observations found four very late scaffold thrombosis in 171 patients treated with a polymeric BRS with a longer degradation time compared with DREAMS 2G. All of those were associated with scaffold discontinuity, mal-apposed, and/or uncovered scaffold struts potentially promoting thrombotic events.^[@ehw196C19]^

b.  Magnesium has a negatively charged surface promoting anti-thrombotic properties *in vivo*.^[@ehw196C1],[@ehw196C20]^ However, this advantage might be hypothetical as the scaffold has been shown to be covered and embedded in the vessel prior to the absorption of the drug--polymer coating.

c.  DREAMS 2G is laser-polished, leading to a very smooth surface.^[@ehw196C6]^

d.  While struts of absorbable scaffolds are thicker than DES struts, the strut cross section of DREAMS 2G is rectangular with rounded edges,^[@ehw196C1]^ which might result in better embedding into the vessel wall.

e.  DREAMS 2G does not require stepwise inflation as required with polymeric scaffolds,^[@ehw196C21]^ which may result in better expansion and apposition.

Vasodilatation or vasoconstriction \>3% was already observed at 6 months, and continued to increase at 12 months. In general, angiographic, IVUS, and OCT parameters remained stable between 6 and 12 months, yet there was a small, but significant decrease in median minimal lumen area when serially measured by OCT in 11 patients (−0.25 mm^2^, IQR: −0.64 to −0.09, *P* = 0.032). Given the very small number of patients included in the intracoronary imaging sub-study, these findings should be interpreted with caution. Since DREAMS 2G was designed to provide a longer scaffolding time compared with DREAMS 1G, it may be assumed that late lumen enlargement is postponed and unlikely to be seen as early as after 1 year. Additional longer-term follow-up evaluation is required to confirm luminal enlargement, as shown for other polymeric scaffolds or previous versions of the magnesium scaffold implanted in the PROGRESS and BIOSOLVE-I studies.^[@ehw196C5],[@ehw196C8],[@ehw196C24]^

Limitations {#s4a}
-----------

As with most first-in-man trials, BIOSOLVE-II was not randomized and included a limited population with simple lesions. Consequently, comparisons with other devices have to be interpreted with caution.

The clinical follow-up rate was high, but---attributed to the fact that it was voluntary per protocol---only a relatively small cohort was available for serial QCA, IVUS, and OCT assessments. The demographics of these patients were comparable to those of the overall study cohort, but nevertheless A further limitation is that long-term data are pending to document lumen enlargement---as seen in BIOSOLVE-I at 3 years.^[@ehw196C24]^ Finally, the favourable outcomes of BIOSOLVE-II need to be confirmed in more complex patient and lesion scenarios.

a.  the data were only powered for in-segment LLL at 6 month,

b.  eventually, a bias is introduced as symptomatic patients may be more prone to agree to 12-month imaging assessments than asymptomatic patients, and

c.  12-month imaging assessments were not performed in all participating centres.

Conclusion {#s5}
==========

This novel absorbable metal scaffold showed a sustained favourable safety profile up to 12 months and no increase in LLL between 6 and 12 months in a subgroup of 42 patients. No additional TLF event occurred beyond 6 months. These findings suggest that DREAMS 2G can be considered as an alternative to current polymeric BRS.
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